ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
Portfolio Pulse from
ADC Therapeutics SA will host a webcast on December 11, 2024, to provide an update on the LOTIS-7 clinical trial. The trial evaluates the safety and efficacy of ZYNLONTA® in combination with glofitamab in patients with relapsed or refractory diffuse large B-cell lymphoma.
December 06, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADC Therapeutics will provide an update on the LOTIS-7 trial, which could impact investor sentiment based on the trial's preliminary data on ZYNLONTA® and glofitamab for r/r DLBCL.
The announcement of preliminary data from the LOTIS-7 trial is significant for ADC Therapeutics as it involves their product ZYNLONTA®. Positive data could boost investor confidence and stock price, while negative data could have the opposite effect.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100